

AbbVie Inc. (ABBV)


NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001551152

AbbVie Inc. ABBV; healthcare	
Grade	D A B C D E fourth fifth of 371 graded peers percentile 63.2; sampling error 2.5 points; lower is stronger
Rank	235 of 371
Profitability	B/C percentile 40.6
Solvency	C/D percentile 58.9
Growth and financing	C/D percentile 58.7
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$134.0B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	12 of 14
Graded from	filings received through Feb 20, 2026 231 days before the rescans; latest periodic filing 10-Q received Aug 3, 2026
Last close	\$272.45 2026-10-08; market equity \$481.5B
Price used in grade	None



D, the sloth
fourth fifth of its sector; letters are fifths of the 371 graded peers


Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Date	Grade
Mar 21, 2026	C/D
Apr 21, 2026	D
[from Aug]	C/D

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 20, 2026

AbbVie or "the company" refer to AbbVie Inc., or AbbVie Inc. and its consolidated subsidiaries, as the context requires. AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious

diseases. AbbVie was incorporated in Delaware on April 10, 2012.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 40.6						
Gross profitability		32.1%	32.2%	46.6	372	2025-12-31
Return on invested capital		17.8%	9.3%	24.7	74	2025-12-31
Accruals ratio		(11.0%)	(6.6%)	38.5	811	2025-12-31
Gross margin stability, five years		3.0 pts	2.8 pts	52.5	243	2025-12-31
Solvency, sleeve percentile 58.9						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30 one or more required annual facts are missing
Altman Z double-prime		not computable	(0.31)			
Net debt to EBITDA		3.39x	1.82x	71.6	75	2025-12-31
Interest coverage		5.21x	(4.51x)	12.5	81	2025-12-31
Current ratio		0.67x	2.96x	92.6	839	2025-12-31
Growth and financing, sleeve percentile 58.7						
Revenue growth, three-year compound		1.8%	10.0%	67.6	415	2025-12-31
Free cash flow growth, three-year compound		(9.8%)	10.9%	85.3	96	2025-12-31
Reinvestment rate		(6.3%)	37.1%	72.8	104	2025-12-31
Asset growth, three years		(1.2%)	2.1%	53.8	704	2025-12-31
Net share issuance, one year		0.2%	2.5%	13.9	634	2026-02-10

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
230	Mannkind Corp. (MNKD)	61.9	C/D	
231	Strata Critical Medical, Inc. (SRTA)	62.2	C/D	short runway, fortress balance sheet
232	Embecta Corp. (EMBC)	62.4	C/D	late filer
233	Biogen Inc. (BIIB)	62.7	D	
234	Lenz Therapeutics, Inc. (LENZ)	63.0	D	short runway
235	AbbVie Inc. (ABBV) <	63.2	D	
236	Caribou Biosciences, Inc. (CRBU)	63.5	D	short runway
237	Royalty Pharma plc (RPRX)	63.8	D	
238	Integra Lifesciences Holdings Corp. (IART)	64.1	D	

239	Alpha Teknova, Inc. (TKNO)	64.3	D
240	Arvinas, Inc. (ARVN)	64.6	D short runway, fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	14.2%	8.0%	54
Distance from 52-week high	0.0%	(31.4%)	98
EBIT to enterprise value	2.8%	(1.5%)	65
Free cash flow yield	3.7%	(1.0%)	73
Book value to price	(0.01)	0.28	10
Sales to price	0.13	0.31	31
Composite equity issuance, five years	(20.6%)	20.3%	7
Relative strength against the sector, log excess return	(0.08)	(0.14)	54

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 7 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$6.6B
Operating cash flow, four quarters	\$19.5B
Months of runway	not finite
Days since last periodic filing	67 (10-Q received Aug 3, 2026)
Median daily dollar volume, 63 sessions	\$1.2B

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$61.2B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$18.2B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
3	assets	us-gaap:Assets	\$134.0B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
4	operating income	us-gaap:OperatingIncomeLoss	\$15.1B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$66.5B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
6	income tax	us-gaap:IncomeTaxExpenseBenefit	\$2.4B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
7	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$58.9B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
8	book equity	us-gaap:StockholdersEquity	-\$3.3B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$5.2B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
10	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$60.3B	2024-12-31	2026-02-20	10-K	0001551152-26-000008
11	book equity	us-gaap:StockholdersEquity	\$3.3B	2024-12-31	2026-02-20	10-K	0001551152-26-000008
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$5.5B	2024-12-31	2026-02-20	10-K	0001551152-26-000008
13	net income	us-gaap:NetIncomeLoss	\$4.2B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$19.0B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
15	assets	us-gaap:Assets	\$135.2B	2024-12-31	2026-02-20	10-K	0001551152-26-000008
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$56.3B	2024-12-31	2026-02-20	10-K	0001551152-26-000008
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$16.9B	2024-12-31	2026-02-20	10-K	0001551152-26-000008
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$54.3B	2023-12-31	2026-02-20	10-K	0001551152-26-000008

19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$20.4B	2023-12-31	2026-02-20	10-K	0001551152-26-000008
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$58.1B	2022-12-31	2025-02-14	10-K	0001551152-25-000020
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$17.4B	2022-12-31	2025-02-14	10-K	0001551152-25-000020
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$56.2B	2021-12-31	2024-02-20	10-K	0001551152-24-000011
23	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$17.4B	2021-12-31	2024-02-20	10-K	0001551152-24-000011
24	depreciation amortization	us-gaap:Depreciation	\$762.0M	2025-12-31	2026-02-20	10-K	0001551152-26-000008
25	interest expense	us-gaap:InterestExpense	\$2.9B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
26	current assets	us-gaap:AssetsCurrent	\$29.1B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
27	current liabilities	us-gaap:LiabilitiesCurrent	\$43.3B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.2B	2025-12-31	2026-02-20	10-K	0001551152-26-000008
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$18.8B	2024-12-31	2026-02-20	10-K	0001551152-26-000008
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$974.0M	2024-12-31	2026-02-20	10-K	0001551152-26-000008
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$22.8B	2023-12-31	2026-02-20	10-K	0001551152-26-000008
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$777.0M	2023-12-31	2026-02-20	10-K	0001551152-26-000008
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$24.9B	2022-12-31	2025-02-14	10-K	0001551152-25-000020
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$695.0M	2022-12-31	2025-02-14	10-K	0001551152-25-000020
35	current assets	us-gaap:AssetsCurrent	\$25.6B	2024-12-31	2026-02-20	10-K	0001551152-26-000008
36	current liabilities	us-gaap:LiabilitiesCurrent	\$38.7B	2024-12-31	2026-02-20	10-K	0001551152-26-000008
37	assets	us-gaap:Assets	\$134.7B	2023-12-31	2025-02-14	10-K	0001551152-25-000020
38	assets	us-gaap:Assets	\$138.8B	2022-12-31	2024-02-20	10-K	0001551152-24-000011
39	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,768,169,012	2026-02-10	2026-02-20	10-K	0001551152-26-000008
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,765,354,859	2025-01-31	2025-02-14	10-K	0001551152-25-000020